ABSTRACT
The rapid expansion of the nanotechnology and nanomedicine
markets presents complex policy and regulatory issues that tradi-
tional schemes are ill-equipped to sufficiently address. In addition,
existing statutes and regulations leave governments and regulatory
agencies unable to effectively respond to the challenges posed
by nanomaterials used for medical applications [1]. Regulatory
frontiers in the field of nanomedicine include areas such as
product safety, privacy and civil liberties, occupational health and
safety (OH&S), intellectual property (IP), international law, and
environmental law, among others [2].
